June 4, 2026
NewLimit
NewLimit is a longevity biotech company focused on rewriting longevity science through cell age reprogramming therapy.
- Round
- Series C
- Amount raised
- $435M
- Lead investor
- —
- Industry
- Biotechnology
- Headquarters
- United States
- Employees
- —
- Website
- —
- —